Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2010-12-01
2011-12-13
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S178000
Reexamination Certificate
active
08076316
ABSTRACT:
The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.
REFERENCES:
patent: 2243887 (1941-06-01), Serini et al.
patent: 2267257 (1941-12-01), Ruzicka
patent: 2308833 (1943-01-01), Ruzicka et al.
patent: 2830063 (1958-04-01), Clinton et al.
patent: 3029263 (1962-04-01), Campbell et al.
patent: 3128292 (1964-04-01), Counsell
patent: 3176030 (1965-03-01), Huffmann et al.
patent: 3200113 (1965-08-01), Christiansen et al.
patent: 3734935 (1973-05-01), Husbands et al.
patent: 3944576 (1976-03-01), Van den Broek
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 5028631 (1991-07-01), Schwartz et al.
patent: 5075464 (1991-12-01), Blohm et al.
patent: 5206008 (1993-04-01), Loria
patent: 5292730 (1994-03-01), Lardy
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5372996 (1994-12-01), Labrie
patent: 5387583 (1995-02-01), Loria
patent: 5424463 (1995-06-01), Lardy et al.
patent: 5461042 (1995-10-01), Loria
patent: 5506223 (1996-04-01), Lardy et al.
patent: 5593981 (1997-01-01), Labrie
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5723455 (1998-03-01), Tanabe et al.
patent: 5763433 (1998-06-01), Morfin
patent: 5824668 (1998-10-01), Rubinfeld et al.
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5912240 (1999-06-01), Loria
patent: 5922701 (1999-07-01), Araneo
patent: 5925630 (1999-07-01), Upasani et al.
patent: 5939545 (1999-08-01), Upasani et al.
patent: 6110906 (2000-08-01), Labrie et al.
patent: 6436435 (2002-08-01), Rubinfeld et al.
patent: 6573289 (2003-06-01), Tasaka et al.
patent: 6667299 (2003-12-01), Ahlem et al.
patent: 6767903 (2004-07-01), Cleve et al.
patent: 7462610 (2008-12-01), Lardy et al.
patent: 7482334 (2009-01-01), Frincke et al.
patent: 7524835 (2009-04-01), Frincke
patent: 7550450 (2009-06-01), Lardy et al.
patent: 7691835 (2010-04-01), Frincke
patent: 7696189 (2010-04-01), Frincke
patent: 7842680 (2010-11-01), Lardy et al.
patent: 7863261 (2011-01-01), Frincke
patent: 2003/0060425 (2003-03-01), Ahlem et al.
patent: 2004/0043973 (2004-03-01), Ahlem et al.
patent: 2006/0079492 (2006-04-01), Ahlem et al.
patent: 2006/0088473 (2006-04-01), Dowding et al.
patent: 2007/0014719 (2007-01-01), Reading et al.
patent: 2007/0077201 (2007-04-01), Reading et al.
patent: 2007/0129282 (2007-06-01), Ahlem et al.
patent: 2008/0153792 (2008-06-01), Frincke et al.
patent: 0 363 128 (1990-04-01), None
patent: WO 91/00732 (1991-01-01), None
patent: WO 95/07926 (1995-03-01), None
patent: WO 95/10527 (1995-04-01), None
patent: WO 97/37662 (1997-10-01), None
patent: WO 99/63973 (1999-12-01), None
patent: WO 00/32201 (2000-06-01), None
patent: WO 00/56757 (2000-09-01), None
U.S. Appl. No. 60/124,087, filed Nov. 3, 1999, Prendergast et al.
U.S. Appl. No. 60/126,056, filed Mar. 23, 1999, Ahlem et al.
Ben-David et al., Anti-hypocholterolemic effects of dihydroepiandersterone in ratsProc. Soc. Exp. Biol. Med., 125:1136-40 1967.
Campbell, et al., 6-methyl steroids in the androstane series.J. Amer. Chem. Soc. 80:4717-4721 1958.
Campbell, et al., The synthesis of some 7α- and 7β-methyl steroid hormones,J. Amer. Chem. Soc., 81:4069-4074 1959.
Chambaz, et al., Urinary steroids in neonates: Characterization of four androstenetetrols by gas chromatography and mass spectrometry.Proceedings of Acad. Sc. Paris, Series D, 268: 2817-2820 1969.
Chang, et al., Suppression of Δ5-Androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells,Proc. Natl. Acad. Sci. USA. 96(20):11173-11177 1999.
Clinton, et al., Esters of 17α-Ethinylandrostane-3β,17β-diol and 17α-ethinylandrost-5-ene-3β,17β-diol,J. Org. Chem. 22:473-475 1957.
Ferrari, et al., Inhibition of β-hydroxysteroid dehydrogenase 1. Structural characteristics of some steroidal inhibitors,Biochem. Biophys. Acta77:349-356 1963.
Gatto, et al., Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptorOncol. Rep.5(1):241-3 1998.
Gaunt, et al., Antagonists to cortisone: an ACTH-like action of steroids,Endocrinol. 52:407-423 1953.
Hackenberg et al., Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3β,17β-diol in human mammary cancer cells,J. Steroid Biochem. Mol. Biol., 46(5):597-603 1993.
Henderson, Dehydroepiandrosterone and 16α-bromo-epiandrosterone: Inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes,Carcinogenesis, 2(7):683-686 1981.
Lardy, et al., Ergosteroids. II: Biologically active metabolites and synthetic derivatives of dehydroepiandrosterone,Steroids63:158-165 1998.
Marwah, et al., C19-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists,Bioorg. Med. Chem., 14:5933-5947 2006.
Miyamoto, et al., Δ5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells,Proc. Natl. Acad. Sci.U. S A. 95(19):11083-11088 1998.
Miyamoto, et al.,3β-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity,Proc. Natl. Acad. Sci.USA, 100:4440-4444 2003.
Moore, et al. Concentration of dihydrotestosterone and 3α-androstanediol in naturally occurring and androgen-induced prostatic hyperplasia in the dog, J.Clin. Invest. 64:1003-1010 1979.
Morfin, et al, Pregnenolone and dehydroepiandersterone as precursors of native 7-hydroxylated metabolites which increases the immune response in mice,J. Steroid Biochem. Mol. Biol. 50:91-100 1994.
Penning, et al., Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones,Biochem J. 351:67-77 2000.
Segaloff, et al., Hormonal therapy in cancer of the breast IV. Effect of androstenediol on clinical course and hormonal excretion,Cancer5(6):1179-1181 1952.
Segaloff, et al., Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretionCancer, 5(2):271-274 1952.
Segaloff, et al., Testosterone and miscellaneous steroids in the treatment of advanced mammary cancer,Cancer, 10(4):808-812 1957.
Shackleton, et al., Metabolism of fetal and neonatal adrenal steroids,J. Steroid. Biochem. 11:523-529 1979.
Harbor BioSciences, Inc.
Muenchau Darryl D.
Peselev Elli
LandOfFree
Steroid compounds and formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Steroid compounds and formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Steroid compounds and formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4304196